The lipid accumulation product is highly related to serum alanine aminotransferase level in male adults

Nutrition Research

Volumn 32, Issue 8, 2012, Pages 581-587

  Ji, Bao Lan ^a   Li, Rong ^a   Zhang, Su Hua ^a   Gong, Li Lin ^a   Wang, Zhi Hong ^a   Ren, Wei ^a   Li, Qi Fu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Abdominal obesity; Alanine aminotransferase; Dyslipidemia; Lipid accumulation product; Nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; INSULIN; LIPID; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID STORAGE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; ALANINE TRANSAMINASE; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FASTING; FATTY LIVER; FEMALE; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; SEX FACTORS; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84865549115     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2012.06.019     Document Type: Article

References (35)

1. Lazo M., Clark J.M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008, 28:339-350.
2. Fan J.G., Farrell G.C. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009, 50:204-210.
3. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
4. Clark J.M., Diehl A.M. Nonalcoholic fatty liver disease: an under recognized cause of cryptogenic cirrhosis. JAMA 2003, 289:3000-3004.
5. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of nonalcoholic fatty live disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
6. Targher G., Bertolini L., Poli F., Rodella S., Scala L., Tessari R., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005, 54:3541-3546.
7. Ioannou G.N., Weiss N.S., Boyko E.J., Mozaffarian D., Lee S.P. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006, 43:1145-1151.
8. Clark J.M., Brancati F.L., Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960-967.
9. Westerbacka J., Cornér A., Tiikkainen M., Tamminen M., Vehkavaara S., Häkkinen A.M., et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 2004, 47:1360-1369.
10. Fraser A., Longnecker M.P., Lawlor D.A. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 2007, 133:1814-1820.
11. Kim W.R., Flamm S.L., Di Bisceglie A.M., Bodenheimer H.C. Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008, 47:1363-1370.
12. Eguchi Y., Eguchi T., Mizuta T., Ide Y., Yasutake T., Iwakiri R., et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol 2006, 41:462-469.
13. van der Poorten D., Milner K.L., Hui J., Hodge A., Trenell M.I., Kench J.G., et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008, 48:449-457.
14. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
15. Kahn H.S. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 2005, 5:26.
16. Després J.P., Cartier A., CÔté M., Arsenault B.J. The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology. Ann Med 2008, 40:514-523.
17. Kallwitz E.R., Kumar M., Aggarwal R., Berger R., Layden-Almer J., Gupta N., et al. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci 2008, 53:1358-1363.
18. Ioachimescu A.G., Brennan D.M., Hoar B.M., Hoogwerf B.J. The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study. Obesity (Silver Spring) 2010, 18:1836-1844.
19. Taverna M.J., Martínez-Larrad M.T., Frechtel G.D., Serrano-Ríos M. Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. Eur J Endocrinol 2011, 164:559-567.
20. Bedogni G., Kahn H.S., Bellentani S., Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol 2010, 10:98.
21. Prati D., Taioli E., Zanella A., Della Torre E., Butelli S., Del Vecchio E., et al. Updated definitions of healthy ranges for serum alanine aminotrans ferase levels. Ann Intern Med 2002, 137:1-10.
22. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
23. Altunkan S., Genç Y., Altunkan E. A comparative study of an ambulatory blood pressure measuring device and a wrist blood pressure monitor with a position sensor versus a mercury sphygmomanometer. Eur J Intern Med 2007, 18:118-123.
24. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
25. Joint committee for Developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese Guidelines on Prevention and Treatment of Dyslipidemia in adults. Chin J Cardiol 2007, 35:390-419. (in Chinese).
26. Geer E.B., Shen W. Gender differences in insulin resistance, body composition, and energy balance. Gend Med 2009, 6:60-75.
27. Bergman R.N., Kim S.P., Catalano K.J., Hsu I.R., Chiu J.D., Kabir M., et al. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity (Silver Spring) 2006, 14:16S-19S.
28. Malhi H., Gores G.J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28:360-369.
29. Buechler C., Wanninger J., Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol 2011, 17:2801-2811.
30. Kim D.S., Jeong S.K., Kim H.R., Kim D.S., Chae S.W., Chae H.J. Effects of triglyceride on ER stress and insulin resistance. Biochem Biophys Res Commun 2007, 363:140-145.
31. Choudhury J., Sanyal A.J. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004, 8:575-594.
32. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42:987-1000.
33. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082-1090.
34. Hou X.H., Zhu Y.X., Lu H.J., Chen H.F., Li Q., Jiang S., et al. Non-alcoholic fatty liver disease's prevalence and impact on alanine aminotransferase associated with metabolic syndrome in the Chinese. J Gastroenterol Hepatol 2011, 26:722-730.
35. Dong M.H., Bettencourt R., Barrett-Connor E., Loomba R. Alanine aminotransferase decreases with age: the Rancho Bernardo Study. PLoS One 2010, 5:e14254.